# Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma

> **NCT00590824** · PHASE2 · COMPLETED · sponsor: **University of Wisconsin, Madison** · enrollment: 23 (actual)

## Conditions studied

- Melanoma

## Interventions

- **DRUG:** hu14.18-IL2
- **DRUG:** hu14.18-IL2

## Key facts

- **NCT ID:** NCT00590824
- **Lead sponsor:** University of Wisconsin, Madison
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12-17
- **Primary completion:** 2018-09-20
- **Final completion:** 2018-09-20
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2019-11-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00590824

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00590824, "Pilot hu14.18-IL2 in Resectable Recurrent Stage III or Stage IV Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00590824. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*